Reading GOVX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GOVX free→Reading GOVX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GOVX free→QuarterlyIQ Insights · GOVX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Unregistered Sales of Equity Securities. The Company has agreed to issue the Pre-Funded Warrants and the Common Warrants pursuant to the exemption from the registration requirements of the Securities Act, available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated thereunder and intends to issue the Common Warrant Shares pursuant to the same exemption. The description of the Pre-Funded Warrants and the Common Warrants under
Entry into a Material Definitive Agreement. Private Placement On May 18, 2026, GeoVax Labs, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in an unregistered private placement (the “Offering”), (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,027,027 shares of the Company’s common stock, $0.001 par value per share (the…
Results of Operations and Financial Condition. On May 14, 2026, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Entry into a Material Definitive Agreement. On May 7, 2026, GeoVax Labs Inc. (the “Company”), entered into common stock warrant exercise inducement offer letters (the “Inducement Letters”) with holders (the “Holders”) of existing warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “common stock”), issued on (i) September 30, 2025, which are exercisable for 150,795 shares of common stock (the “September 2025 Warrants”), and (ii) December 22, 2025, which a…
Unregistered Sales of Equity Securities. The description of the New Warrants under
Results of Operations and Financial Condition. On April 15, 2026, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Entry into a Material Definitive Agreement. On March 31, 2026, GeoVax Labs Inc. (the “Company”), entered into common stock warrant exercise inducement offer letters (the “Inducement Letters”) with holders (the “Holders”) of existing warrants to purchase shares of the Company’s common stock issued on (i) May 21, 2024, which are exercisable for 64,228 shares of common stock (with a current exercise price of $8.22 per share) (the “May 2024 Warrants”), (ii) July 12, 2024, which are exercisable fo…
Unregistered Sales of Equity Securities. The description of the New Warrants under
Entry into a Material Definitive Agreement. Registered Direct Offering On February 13, 2026, GeoVax Labs, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), an aggregate of (i) 402,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) pre-funded warrants…
Unregistered Sales of Equity Securities. The Company has agreed to issue the Common Warrants pursuant to the exemption from the registration requirements of the Securities Act, available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated thereunder and intends to issue the Common Warrant Shares pursuant to the same exemption. The description of the Common Warrants under
Material Modification to Rights of Security Holders To the extent required by
Entry into a Material Definitive Agreement. On December 19, 2025, GeoVax Labs, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), an aggregate of 13,244,896 common units (the “Common Units”), consistin…
Results of Operations and Financial Condition. On November 13, 2025, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Material Modification to Rights of Security Holders. The Company has agreed to issue the Common Warrants pursuant to the exemption from the registration requirements of the Securities Act, available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated thereunder and intends to issue the Common Warrant Shares pursuant to the same exemption. The description of the Common Warrants under
Entry into a Material Definitive Agreement. On September 30, 2025, GeoVax Labs, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with purchasers party thereto pursuant to which the Company agreed to sell, in a registered direct offering (the “Offering”), an aggregate of 3,968,256 shares (the “Shares”) of the Company’s common st…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 31, 2025, the “Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq List…
Results of Operations and Financial Condition. On July 28, 2025, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Entry into a Material Definitive Agreement. On July 1, 2025, GeoVax Labs, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), an aggregate of 9,235,000 common units (the “Common Units”), consisting of (…
Results of Operations and Financial Condition. On May 1, 2025, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Termination of a Material Definitive Agreement. On April 11, 2025, GeoVax, Inc. (the “Company”) received written notification from Advanced Technology International (ATI) (the “Notice”) directing the Company to stop work on all of the Company’s efforts with respect to Project Agreement No. 01; RRPV-24-04-NGVx-006; “NextGen Vaccinations: Phase 2B Clinical Trial Execution: Phase 2b study to evaluate GEO-CM04S1 COVID-19 vaccine” under the Consortium Base Agreement No. 2024-564 (the “Project Agre…
Results of Operations and Financial Condition. On March 27, 2025, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Entry into a Material Definitive Agreement. Registered Direct Offering On March 23, 2025, GeoVax Labs, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with a purchaser pursuant to which the Company agreed to sell, in a registered direct offering (the “Offering”), an aggregate of (i) 1,350,000 shares (the “Shares”) of the…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'None' to 'inexpensive'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.